Clinical Cancer Research, Vol 3, Issue 1 47-50, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Prognostic value of pleural effusion in patients with non-small cell lung cancer

S Sugiura, Y Ando, H Minami, M Ando, S Sakai and K Shimokata
First Department of Internal Medicine, Nagoya University School of Medicine, Nagoya, Japan.

This study was performed to determine whether pleural effusion in patients with advanced non-small cell lung cancer (NSCLC) has a negative impact on survival. We evaluated 12 prognostic factors in 197 patients with stage IIIB or IV NSCLC. Each factor was dichotomized, and survival curves calculated by the Kaplan-Meier technique were compared using the log-rank test. The Cox proportional hazards regression model was used to confirm the significance of each prognostic factor selected by univariate analysis. We compared the survival times for stage IIIB with pleural effusion with those of stage IIIB without effusion and stage IV. To determine the impact of the cytological results of the effusion on survival, we compared the survival times for cytologically positive and negative effusions. Univariate analysis identified eight significant prognostic factors: pleural effusion, node status, stage, performance status, weight loss, hemoglobin, albumin, and lactate dehydrogenase. Pleural effusion was selected as a prognostic factor in the multivariate analysis, together with stage, performance status, albumin, and node status. Median survival times for stage IIIB without effusion, stage IIIB with effusion, and stage IV were 15.3, 7.5, and 5.5 months, respectively (P < 0.0001). Survival time for stage IIIB with effusion was significantly different from that of stage IIIB without effusion (P = 0.0129) but not from that of stage IV (P = 0.0797). Among patients with effusion, no significant difference in survival time was observed between cytologically positive and negative effusions. We conclude that pleural effusion in advanced NSCLC is a prognostic factor. Survival time for stage IIIB with pleural effusion is more similar to that of stage IV rather than that of stage IIIB without effusion.

This article has been cited by other articles:

				R.-P. Perng, C.-Y. Chen, G.-C. Chang, T.-C. Hsia, N.-Y. Hsu, Y.-H. Tsai, C.-M. Tsai, C.-H. Yang, Y.-M. Chen, C.-J. Yu, et al. Revisit of 1997 TNM Staging System--Survival Analysis of 1112 Lung Cancer Patients in Taiwan Jpn. J. Clin. Oncol., January 1, 2007; 37(1): 9 - 15. [Abstract] [Full Text] [PDF]

				A. Tremblay and G. Michaud Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest, February 1, 2006; 129(2): 362 - 368. [Abstract] [Full Text] [PDF]

				G. T. Stathopoulos, Z. Zhu, M. B. Everhart, I. Kalomenidis, W. E. Lawson, S. Bilaceroglu, T. E. Peterson, D. Mitchell, F. E. Yull, R. W. Light, et al. Nuclear Factor-{kappa}B Affects Tumor Progression in a Mouse Model of Malignant Pleural Effusion Am. J. Respir. Cell Mol. Biol., February 1, 2006; 34(2): 142 - 150. [Abstract] [Full Text] [PDF]

				J. S. Friedberg, R. Mick, J. P. Stevenson, T. Zhu, T. M. Busch, D. Shin, D. Smith, M. Culligan, A. Dimofte, E. Glatstein, et al. Phase II Trial of Pleural Photodynamic Therapy and Surgery for Patients With Non-Small-Cell Lung Cancer With Pleural Spread J. Clin. Oncol., June 1, 2004; 22(11): 2192 - 2201. [Abstract] [Full Text] [PDF]

				K.-i. Oonakahara, W. Matsuyama, I. Higashimoto, M. Kawabata, K. Arimura, and M. Osame Stromal-Derived Factor-1{alpha}/CXCL12-CXCR 4 Axis Is Involved in the Dissemination of NSCLC Cells into Pleural Space Am. J. Respir. Cell Mol. Biol., May 1, 2004; 30(5): 671 - 677. [Abstract] [Full Text] [PDF]

				T.-L. Hung, F.-F. Chen, J. M. Liu, W.-W. Lai, A.-L. Hsiao, W.-T. Huang, H. H. W. Chen, and W.-C. Su Clinical Evaluation of HER-2/neu Protein in Malignant Pleural Effusion-Associated Lung Adenocarcinoma and as a Tumor Marker in Pleural Effusion Diagnosis Clin. Cancer Res., July 1, 2003; 9(7): 2605 - 2612. [Abstract] [Full Text] [PDF]

				M. D. Brundage, D. Davies, and W. J. Mackillop Prognostic Factors in Non-small Cell Lung Cancer* : A Decade of Progress Chest, September 1, 2002; 122(3): 1037 - 1057. [Abstract] [Full Text] [PDF]

				G. Hripcsak, J. H. M. Austin, P. O. Alderson, and C. Friedman Use of Natural Language Processing to Translate Clinical Information from a Database of 889,921 Chest Radiographic Reports Radiology, July 1, 2002; 224(1): 157 - 163. [Abstract] [Full Text]

				E. Ruffini, O. Rena, M. Bongiovanni, R. Cristofori, M. Mancuso, P. L. Filosso, M. Molinatti, and G. Maggi The significance of intraoperative pleural effusion during surgery for bronchogenic carcinoma Eur. J. Cardiothorac. Surg., March 1, 2002; 21(3): 508 - 513. [Abstract] [Full Text] [PDF]

				N. Sawabata, A. Matsumura, A. Motohiro, Y. Osaka, K. Gennga, S. Fukai, and T. Mori Malignant minor pleural effusion detected on thoracotomy for patients with non-small cell lung cancer: is tumor resection beneficial for prognosis? Ann. Thorac. Surg., February 1, 2002; 73(2): 412 - 415. [Abstract] [Full Text] [PDF]

				K. Yokoi, H. Matsuguma, and M. Anraku Extrapleural pneumonectomy for lung cancer with carcinomatous pleuritis J. Thorac. Cardiovasc. Surg., January 1, 2002; 123(1): 184 - 185. [Full Text] [PDF]

				F. E. Mott, N. Sharma, and P. Ashley Malignant Pleural Effusion in Non-small Cell Lung Cancer--Time for a Stage Revision? Chest, January 1, 2001; 119(1): 317 - 318. [Full Text] [PDF]

				S. Yano, H. Shinohara, R. S. Herbst, H. Kuniyasu, C. D. Bucana, L. M. Ellis, and I. J. Fidler Production of Experimental Malignant Pleural Effusions Is Dependent on Invasion of the Pleura and Expression of Vascular Endothelial Growth Factor/Vascular Permeability Factor by Human Lung Cancer Cells Am. J. Pathol., December 1, 2000; 157(6): 1893 - 1903. [Abstract] [Full Text] [PDF]

				S. Yano, R. S. Herbst, H. Shinohara, B. Knighton, C. D. Bucana, J. J. Killion, J. Wood, and I. J. Fidler Treatment for Malignant Pleural Effusion of Human Lung Adenocarcinoma by Inhibition of Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Phosphorylation Clin. Cancer Res., March 1, 2000; 6(3): 957 - 965. [Abstract] [Full Text]

				S. S. Leong, C. M. Rocha Lima, C. A. Sherman, and M. R. Green The 1997 International Staging System for Non-Small Cell Lung Cancer: Have All the Issues Been Addressed? Chest, January 1, 1999; 115(1): 242 - 248. [Abstract] [Full Text] [PDF]